Allogenetics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Series A
- (In Progress)
- Investors
-
6
Allogenetics General Information
Description
Developer of an ex vivo gene therapy platform intended to eliminate organ rejection in transplant patients by genetically modifying donor organs to render them immunologically invisible to the recipient's immune system. The company's platform applies viral transduction during organ perfusion to deactivate tissue markers that trigger rejection, enabling transplant patients and centers to eliminate the need for lifelong immunosuppression and improve long-term graft survival.
Contact Information
Website
www.allogenetics.comCorporate Office
- Feodor-Lynen-Straße 5
- Lower Saxony
- 30625 Hannover
- Germany
Corporate Office
- Feodor-Lynen-Straße 5
- Lower Saxony
- 30625 Hannover
- Germany
Allogenetics Timeline
Allogenetics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC (Series A) | 14-Sep-2026 | In Progress | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC | 09-Sep-2026 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC | 30-Aug-2024 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC | 01-Aug-2024 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Jan-2023 | Completed | Startup | |||
| 1. University Spin-Out | 07-Sep-2022 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Allogenetics Patents
Allogenetics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3994264-A1 | Tissue for use as allogeneic or xenogeneic transplant and method for its production | Pending | 04-Jul-2019 | ||
| US-20230010683-A1 | Tissue for use as allogeneic or xenogeneic transplant and method for its production | Pending | 04-Jul-2019 | ||
| AU-2018274161-A1 | Method for genetically modifying a vascularised tissue | Active | 26-May-2017 | ||
| AU-2018274161-B2 | Method for genetically modifying a vascularised tissue | Active | 26-May-2017 | A01N1/126 |
Allogenetics Signals
Allogenetics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Life Science Valley Ventures Management | Venture Capital | Minority | ||
| Ascenion | Accelerator/Incubator | Minority | ||
| CARMA FUND Management | Venture Capital | Minority | ||
| NBank Capital | Venture Capital | Minority | ||
| BioIntelligence | Accelerator/Incubator | Minority |
Allogenetics FAQs
-
When was Allogenetics founded?
Allogenetics was founded in 2022.
-
Where is Allogenetics headquartered?
Allogenetics is headquartered in Hannover, Germany.
-
What is the size of Allogenetics?
Allogenetics has 17 total employees.
-
What industry is Allogenetics in?
Allogenetics’s primary industry is Drug Discovery.
-
Is Allogenetics a private or public company?
Allogenetics is a Private company.
-
What is Allogenetics’s current revenue?
The current revenue for Allogenetics is .
-
How much funding has Allogenetics raised over time?
Allogenetics has raised $11.8M.
-
Who are Allogenetics’s investors?
Life Science Valley Ventures Management, Ascenion, CARMA FUND Management, NBank Capital, and BioIntelligence are 5 of 6 investors who have invested in Allogenetics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process